Literature DB >> 19257826

Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia.

I-Ping Chen1, Chiachien J Wang, Sara Strecker, Boguslawa Koczon-Jaremko, Adele Boskey, Ernst J Reichenberger.   

Abstract

Craniometaphyseal dysplasia (CMD) is a monogenic human disorder characterized by thickening of craniofacial bones and flaring metaphyses of long bones. Mutations for autosomal dominant CMD have been identified in the progressive ankylosis gene ANKH. Previous studies of Ank loss-of-function models, Ank(null/null) and Ank(ank/ank) mice, suggest that Ank plays a role in the regulation of bone mineralization. However, the mechanism for Ank mutations leading to CMD remains unknown. We generated the first knockin (KI) mouse model for CMD expressing a human mutation (Phe377 deletion) in ANK. Homozygous Ank knockin mice (Ank(KI/KI)) replicate many typical features of human CMD including hyperostosis of craniofacial bones, massive jawbones, decreased diameters of cranial foramina, obliteration of nasal sinuses, fusion of middle ear bones, and club-shaped femurs. In addition, Ank(KI/KI) mice have increased serum alkaline phosphatase and TRACP5b, as reported in CMD patients. Biochemical markers of bone formation and bone resorption, N-terminal propeptide of type I procollagen and type I collagen cross-linked C-terminal telopeptide, are significantly increased in Ank(KI/KI) mice, suggesting increased bone turnover. Interestingly, Ank(KI/KI) bone marrow-derived macrophage cultures show decreased osteoclastogenesis. Despite the hyperostotic phenotype, bone matrix in Ank(KI/KI) mice is hypomineralized and less mature, indicating that biomechanical properties of bones may be compromised by the Ank mutation. We believe this new mouse model will facilitate studies of skeletal abnormalities in CMD at cellular and molecular levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19257826      PMCID: PMC2697624          DOI: 10.1359/jbmr.090218

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  39 in total

1.  Role of bone bark during growth in width of tubular bones. A study in human fetuses.

Authors:  G Schollmeier; H K Uhthoff; K U Lewandrowski; K Fukuhara
Journal:  Clin Orthop Relat Res       Date:  1999-10       Impact factor: 4.176

Review 2.  Molecular markers of bone turnover: biochemical, technical and analytical aspects.

Authors:  M J Seibel
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

Review 3.  Bone development.

Authors:  B R Olsen; A M Reginato; W Wang
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

Review 4.  Craniometaphyseal dysplasia: a case report and review of medical and surgical management.

Authors:  William M Sheppard; Robert J Shprintzen; Sherard A Tatum; Charles I Woods
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2003-01       Impact factor: 1.675

5.  Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK.

Authors:  E Reichenberger; V Tiziani; S Watanabe; L Park; Y Ueki; C Santanna; S T Baur; R Shiang; D K Grange; P Beighton; J Gardner; H Hamersma; S Sellars; R Ramesar; A C Lidral; A Sommer; C M Raposo do Amaral; R J Gorlin; J B Mulliken; B R Olsen
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

6.  Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia.

Authors:  P Nürnberg; H Thiele; D Chandler; W Höhne; M L Cunningham; H Ritter; G Leschik; K Uhlmann; C Mischung; K Harrop; J Goldblatt; Z U Borochowitz; D Kotzot; F Westermann; S Mundlos; H S Braun; N Laing; S Tinschert
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

7.  Mutations in ANKH cause chondrocalcinosis.

Authors:  Adrian Pendleton; Michelle D Johnson; Anne Hughes; Kyle A Gurley; Andrew M Ho; Michael Doherty; Josh Dixey; Pierre Gillet; Damien Loeuille; Rodney McGrath; Antonio Reginato; Rita Shiang; Gary Wright; Patrick Netter; Charlene Williams; David M Kingsley
Journal:  Am J Hum Genet       Date:  2002-09-20       Impact factor: 11.025

8.  Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH.

Authors:  Charlene J Williams; Yun Zhang; Andrew Timms; Gina Bonavita; Francisco Caeiro; John Broxholme; Jonathan Cuthbertson; Yvonne Jones; Raul Marchegiani; Antonio Reginato; R Graham G Russell; B Paul Wordsworth; Andrew J Carr; Matthew A Brown
Journal:  Am J Hum Genet       Date:  2002-09-17       Impact factor: 11.025

9.  Role of the mouse ank gene in control of tissue calcification and arthritis.

Authors:  A M Ho; M D Johnson; D M Kingsley
Journal:  Science       Date:  2000-07-14       Impact factor: 47.728

10.  Null mutations in human and mouse orthologs frequently result in different phenotypes.

Authors:  Ben-Yang Liao; Jianzhi Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

View more
  22 in total

1.  Novel ANKH mutation in a patient with sporadic craniometaphyseal dysplasia.

Authors:  Allison Zajac; Seung-Hak Baek; Imad Salhab; Melissa A Radecki; Sukwha Kim; Hakon Hakonarson; Hyun-Duck Nah
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

2.  Dental abnormalities in a mouse model for craniometaphyseal dysplasia.

Authors:  E H Dutra; I-P Chen; E J Reichenberger
Journal:  J Dent Res       Date:  2012-11-15       Impact factor: 6.116

Review 3.  Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease.

Authors:  Florence W L Tsui
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

4.  A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD).

Authors:  I-Ping Chen; Liping Wang; Xi Jiang; Hector Leonardo Aguila; Ernst J Reichenberger
Journal:  Hum Mol Genet       Date:  2010-12-13       Impact factor: 6.150

5.  The progressive ankylosis protein regulates cementum apposition and extracellular matrix composition.

Authors:  B L Foster; K J Nagatomo; S O Bamashmous; K A Tompkins; H Fong; D Dunn; E Y Chu; C Guenther; D M Kingsley; R B Rutherford; M J Somerman
Journal:  Cells Tissues Organs       Date:  2011-03-09       Impact factor: 2.481

6.  Autosomal recessive mental retardation, deafness, ankylosis, and mild hypophosphatemia associated with a novel ANKH mutation in a consanguineous family.

Authors:  Eva Morava; Jirko Kühnisch; Jefte M Drijvers; Joris H Robben; Cor Cremers; Petra van Setten; Amanda Branten; Sabine Stumpp; Alphons de Jong; Krysta Voesenek; Sascha Vermeer; Angelien Heister; Hedi L Claahsen-van der Grinten; Charles W O'Neill; Michèl A Willemsen; Dirk Lefeber; Peter M T Deen; Uwe Kornak; Hannie Kremer; Ron A Wevers
Journal:  J Clin Endocrinol Metab       Date:  2010-10-13       Impact factor: 5.958

7.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

8.  Dental Anomalies Associated with Craniometaphyseal Dysplasia.

Authors:  I-P Chen; A Tadinada; E H Dutra; A Utreja; F Uribe; E J Reichenberger
Journal:  J Dent Res       Date:  2014-03-24       Impact factor: 6.116

Review 9.  The role of SH3BP2 in the pathophysiology of cherubism.

Authors:  Ernst J Reichenberger; Michael A Levine; Bjorn R Olsen; Maria E Papadaki; Steven A Lietman
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

10.  Increased risk of temporomandibular joint closed lock: a case-control study of ANKH polymorphisms.

Authors:  Boyen Huang; Katsu Takahashi; Tomoko Sakata; Honoka Kiso; Manabu Sugai; Kazuma Fujimura; Akira Shimizu; Shinji Kosugi; Tosiya Sato; Kazuhisa Bessho
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.